Introduction {#s1}
============

During every round of eukaryotic cell division, a small amount of DNA is lost from the ends of each chromosome ([@bib44]; [@bib58]). Termed the end replication problem, this phenomenon is countered by two complementary adaptations. First, repetitive noncoding DNA sequences, known as telomeres, are found at chromosomal ends, preventing the loss of vital genetic information during each cell division ([@bib7]; [@bib37]). Second, the ribonucleoprotein telomerase elongates shortened telomeres at chromosomal ends using a reverse transcriptase activity ([@bib25]). Without elongation, telomeres will eventually reach a critically short length, causing cells to undergo apoptosis or become senescent ([@bib26]; [@bib35]). Because telomerase plays such a fundamental role in the temporal regulation of cell division, aberrations in telomerase are implicated in numerous human diseases. These include premature aging, idiopathic pulmonary fibrosis (IPF), dyskeratosis congenita, and cancer ([@bib8]; [@bib30]; [@bib39]). In particular,\~90% of cancers upregulate telomerase to combat telomere shortening and enable unlimited cell division, as opposed to somatic cells where telomerase is absent ([@bib27]).

The implication of telomerase in multiple human diseases underscores the importance of understanding its catalytic cycle at the molecular level. Although the human telomerase holoenzyme is composed of multiple accessory subunits, catalysis is localized to the telomerase reverse transcriptase (TERT) subunit ([@bib40]). Historically, biochemical characterization of human TERT (*h*TERT) has proven challenging, in part because of technical difficulties purifying and reconstituting large quantities of active telomerase ([@bib47]; [@bib50]). As a result, many fundamental parameters describing the telomerase catalytic cycle have remained undefined. These enzymatic constants are essential for understanding the roles of active site residues, the selection of right from the wrong nucleotides (fidelity), and the prevention of ribonucleotide triphosphate (rNTP) insertion (sugar discrimination). The faithful extension of telomeres by telomerase is critical because aberrations in telomeric sequences prevent shelterin proteins from capping telomeres, thus promoting genomic instability ([@bib16]; [@bib38]). Structural studies of human telomerase have also been historically challenging. Currently, the highest resolution structural snapshot of human telomerase is a cryo-EM structure at 8 Å resolution ([@bib40]). This structure represents a milestone in telomerase structural biology, revealing details of the telomerase tertiary and secondary structure. However, the positions of amino acids are difficult to distinguish at this resolution, leaving many molecular details of the catalytic cycle ambiguous.

To mitigate the difficulties inherent in the biochemical characterization of human telomerase, several model systems have been established. These include models from yeast, the protazoa *Tetrahymena thermophila* (with which a 5 Å cryo-EM structure was recently determined), and the insect model *Tribolium castaneum* (sequence alignment shown in [Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}; [@bib23]; [@bib28]; [@bib45]). For biochemical characterization of TERT, we opted to use *T. castaneum* TERT (*tc*TERT) for the following reasons: first, *tc*TERT readily fit into the cryo-EM density of *h*TERT and aligns well with the recent cryo-EM structure from *T. thermophila*, highlighting the conserved secondary structure ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}); second, upon alignment with *h*TERT, the active site pocket of *tc*TERT exhibits a high degree of sequence identity ([Supplementary file 1](#supp1){ref-type="supplementary-material"}, Table 1a); third, using a truncated version of the *T. castaneum* telomerase RNA component (TR), we can readily obtain sufficient quantities of isolated, active *tc*TERT for characterization of the telomerase catalytic cycle by pre-steady-state kinetics and X-ray crystallography ([@bib23]; [@bib40]). Although TERTs have highly conserved active sites, there are significant changes in the domain architecture between human and *tc*TERT. These include *tc*TERT lacking the N-terminal (TEN) domain and missing a portion of the insertion in fingers domain (IFD) ([Supplementary file 1](#supp1){ref-type="supplementary-material"}, Table 1b). These domains are essential for the activity of other telomerase homologs, and have been hypothesized to be particularly important for telomerase ratcheting during translocation ([@bib54]). Therefore, we kept our *tc*TERT kinetics within a single turnover (i.e. insertion) regime, and, wherever possible, complemented the kinetic results with human telomerase studies to characterize the catalytic cycle of telomerase. Using this combined approach, we have elucidated the role of conserved telomerase active site residues and determined the mechanisms of fidelity and rNTP discrimination.

Results {#s2}
=======

The TERT subunit of telomerase elongates telomeric DNA using a conserved catalytic cycle as outlined in [Figure 1A](#fig1){ref-type="fig"}, [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"}, and here. First, telomerase anneals its RNA template to the end of telomeric DNA to form a binary complex (TERT:DNA, [Figure 1A](#fig1){ref-type="fig"}, state A~1~). Next, the binary complex binds an incoming dNTP and samples for proper Watson-Crick base pairing to the RNA template ([Figure 1A](#fig1){ref-type="fig"}, state B~1~). The transition between these two states represents the nucleotide binding step, measured as a dissociation constant (K~d~). If the resulting ternary complex (TERT:DNA:dNTP) is in the proper orientation, TERT will catalyze the formation of a phosphodiester bond and extend the telomere by one nucleotide ([Figure 1A](#fig1){ref-type="fig"}, state C~1~). The transition between these two states is the chemistry step, and its theoretical maximum rate with saturating nucleotide concentration is described as k~pol~. Following insertion of the incoming nucleotide, telomerase will shift registry to align the active site with the next templating base (forming state A~2~). This core catalytic cycle repeats six times, until a new telomeric repeat is added ([Figure 1A](#fig1){ref-type="fig"}, state C~6~). All 18 telomerase states that are required to add one telomeric repeat are shown in [Figure 1---figure supplement 3](#fig1s3){ref-type="fig"} for reference. Importantly, as the telomerase approaches the end of its template, the DNA:RNA duplex at the 5' end begins to melt, enabling telomerase to either (1) translocate and anneal the RNA component to the newly extended telomeric repeat, thus allowing for additional repeat addition; or (2) dissociate from the telomeric DNA. The number of times that a single telomerase enzyme traverses this catalytic cycle is tightly regulated. It was recently shown telomerase becomes inactive after two repeats, but can be reactivated by the recently discovered intracellular telomerase-activating factors (iTAFs) ([@bib49]).

![The telomerase catalytic cycle, and its first structural state.\
(**A**) Overview of the telomerase catalytic cycle. Telomerase forms a prenucleotide bound binary complex (State A~1~). Then, it binds the incoming nucleotide triphosphate to form a ternary complex (State B~1~), chemically links it to the telomere terminus (State C~1~), and then shifting registry to bind the next incoming nucleotide (State A~2~). After this cycle completes six times (State C~6~), telomerase will either disassociate or undergo translocation (dotted line), which places it back into State A~1~. (**B**) The tcTERT prenucleotide binary complex. tcTERT (pale orange cartoon and surface) encircles the DNA (white) and RNA (purple) substrate. (**C**) Active site pocket of the prenucleotide binary complex. rC binding (gray), dG binding residues (yellow), nucleoside residues (cyan), catalytic residues (blue), and triphosphate binding (green) are shown as sticks. (**D**) Closeup views of the rC binding residues, (**E**) terminal dG binding residues, (**F**) nucleoside binding residues, and (**G**) the tcTERT catalytic residues and triphosphate coordinating residues. A Mg2+ ion is shown as a purple sphere and DNA is presented as white sticks.](elife-55438-fig1){#fig1}

Observing telomeric extension at the molecular level {#s2-1}
----------------------------------------------------

### Pre-nucleotide binary complex {#s2-1-1}

We determined how TERT engages with telomeric DNA by co-crystallizing *tc*TERT with a 16-mer RNA strand hybridized to its complementary 15-mer DNA strand to form a binary complex. This substrate mimics the initial TERT:RNA complex bound to telomeric DNA ([Figure 1A](#fig1){ref-type="fig"}, state A~6~). In this orientation, an unpaired 5' cytosine (rC) of the RNA strand acts as the templating base and a 3' adenosine (dA) of the DNA strand serves as the primer terminus ([Figure 1B,C](#fig1){ref-type="fig"}). Crystals of this complex grew in a P3~2~21 space group, diffracting to 2.5 Å resolution ([Supplementary file 2](#supp2){ref-type="supplementary-material"}, Table 2a). The resulting structure shows TERT bound as a ring around the end of the RNA:DNA complex, with its active site positioned at the terminus of the DNA strand ([Figure 1B,C](#fig1){ref-type="fig"}).

Within the TERT active site, the templating RNA strand is stabilized by multiple conserved tcTERT residues ([Supplementary file 1](#supp1){ref-type="supplementary-material"}, Table 1a). Residues I196, V197, S198, G309, and R194 compose a pocket around the templating RNA base ([Figure 1D](#fig1){ref-type="fig"}). This pocket uses both polar and nonpolar interactions to stabilize the templating rC in a conformation that orients its Watson-Crick edge towards the incoming nucleotide binding site. On the opposite side, the 3'-OH of the primer terminal 3'-dA points towards the catalytic metal binding site, and side chains from T341 and V342 coordinate the deoxyribose sugar moiety of the 3'-dA with nonpolar interactions ([Figure 1E](#fig1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}, Table 1a). This binary TERT complex also has a cavity in the active site that forms the nucleotide binding pocket. These nucleotide pocket residues can be subdivided into three categories: nucleoside coordinating, catalytic, and triphosphate interacting residues ([Figure 1F and G](#fig1){ref-type="fig"}). Notably, the residues that compose these three groups are 100% conserved between *h*TERT and *tc*TERT ([Supplementary file 1](#supp1){ref-type="supplementary-material"}, Table 1a). The nucleoside binding group is composed of residues R194, Y256, and Q308 ([Figure 1F](#fig1){ref-type="fig"}). These residues form a nucleoside shaped cleft directly upstream of the primer terminus of the telomeric DNA and are further characterized below. The catalytic residues include the catalytic triad: D251, D343, and D344. These residues coordinate the divalent metal ions during catalysis ([Figure 1G](#fig1){ref-type="fig"}). Residues K189, A255, N369, and the backbone of K372 are in position to form interactions with the triphosphate of the incoming nucleotide ([Figure 1G](#fig1){ref-type="fig"}). Collectively, the active site of *tc*TERT is primed for nucleotide binding, and the residues involved in binding are highly conserved with human telomerase ([Supplementary file 1](#supp1){ref-type="supplementary-material"}, Table 1a).

Nucleotide bound ternary complex {#s2-2}
--------------------------------

We also determined the structure of TERT after binding an incoming nucleotide, but prior to catalysis ([Figure 1A](#fig1){ref-type="fig"}, state B~6~). To capture the ternary complex, we utilized a non-hydrolyzable nucleotide analog 2\'-deoxyguanosine-5\'-\[(α,β)-methyleno\]triphosphate (dGpCpp). dGpCpp is identical to dGTP, except the bridging oxygen between the α and β phosphate is a carbon atom, which prevents catalysis ([@bib3]; [@bib24]). Crystals of this complex grew in the same P3~2~21 space group and diffracted to 2.9 Å resolution ([Supplementary file 2](#supp2){ref-type="supplementary-material"}, Table 2a). Comparing this ternary complex to the binary state (RMSD value of 1.52 Å, [Figure 2A](#fig2){ref-type="fig"}) indicates minimal structural rearrangements are required for TERT to bind dGpCpp. The active site residues that compose the nucleotide binding pocket of the pre-nucleotide binary complex coordinate the incoming dGpCpp, positioning its Watson-Crick face to hydrogen bond with the templating rC ([Figure 2B,C](#fig2){ref-type="fig"}). Two Mg^+2^ ions exhibit octahedral coordination to facilitate nucleotide binding. The catalytic metal coordinates residues D251, D343, D344, the 3'-OH of the primer terminus, and the non-bridging oxygen of the dGpCpp α-phosphate ([Figure 2D](#fig2){ref-type="fig"}). The nucleotide metal coordinates the side chains of D251 and D343, the backbone carbonyl of I252, and a non-bridging oxygen on the α,β, and γ phosphates of the incoming dGpCpp ([Figure 2D](#fig2){ref-type="fig"}). Nucleoside binding residue R194 remains in a similar position to where it was in the prenucleotide state, but now forms a network of contacts between residue Q308 and the α phosphate of the incoming nucleotide, stabilizing it in an orientation near other nucleoside binding residues. Y256 is positioned near the C2 position of the deoxyribose sugar portion of the nucleoside, and Q308 coordinates the nucleoside component of the dGpCpp ([Figure 2E](#fig2){ref-type="fig"}). As a whole, the nucleoside binding residues encircle the nucleoside component of the incoming nucleotide, and position it so that the nucleobase can base stack with the primer terminus. Overall, this ternary complex provides insight into nucleotide selection by TERT and the specific roles of active site residues during nucleotide binding.

![TERT ternary and product structures.\
(**A**) The tcTERT ternary structure, overlayed with the prenucleotide binary complex. DNA (white), RNA (purple), binary tcTERT (yellow cartoon), and ternary tcTERT (blue cartoon) are shown. (**B**) The tcTERT active site. Nucleoside residues (cyan), triphosphate residues (green), and catalytic residues (blue) are shown. The dGpCpp (yellow), DNA, and RNA are represented as sticks. (**C**) Closeup view of dGpCpp with a polder OMIT map contoured at σ = 3.0 (green mesh). (**D, E**) dGpCpp contacts are shown with Mg2+ (purple), catalytic residues (marine) and nucleoside residues (cyan) indicated. (**F**) The tcTERT product structure (red cartoon), overlaid with the prenucleotide binary complex (yellow cartoon). (**G**) An active site view of the tcTERT product structure. (**H**) A display of a polder OMIT map contoured at σ = 3.3 around the incoming dGpCpp (green mesh). (**I**) Catalytic residues (marine) coordinate the inserted dG (white).](elife-55438-fig2){#fig2}

Product complex {#s2-3}
---------------

To capture a product complex of telomerase, we crystallized TERT after incubation with its nucleic acid substrate and dGTP, allowing TERT to insert the nucleotide and form the final product stage of the catalytic cycle ([Figure 1A](#fig1){ref-type="fig"}, state C~6~). Both globally and within the active site, we observed minimal structural changes between the prenucleotide binary complex and the product structure (RMSD value of 1.04 Å, [Figure 2F](#fig2){ref-type="fig"}). Electron density of the inserted dG indicates its Watson-Crick face hydrogen bonds to the Watson-Crick face of the templating rC ([Figure 2G,H](#fig2){ref-type="fig"}). The templating rC continues to interact with the residues that coordinated it during the other two structural states described prior, including I196, V197, S198, G309, and R194. Neither a registry shift nor a translocation step has occurred in this structure; the TERT active site remains aligned to the terminal DNA base ([Figure 2I](#fig2){ref-type="fig"}). Comparing this structure to structures of the previous stages in the catalytic cycle, we observed that minimal global rearrangements are required to proceed from the binary, ternary, and product states of the catalytic cycle.

Fidelity and sugar selectivity of TERT {#s2-4}
--------------------------------------

Characterization of the telomerase catalytic mechanism was performed using pre-steady-state kinetics of single nucleotide insertion by *tc*TERT ([Figure 3](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}, [Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}, and [Supplementary file 3](#supp3){ref-type="supplementary-material"}). These experiments determined both the *K*~d~ of the incoming nucleotide and the *k*~pol~ for nucleotide insertion by *tc*TERT, which have thus far proven unattainable for human telomerase (or any other homolog). TERT inserts the correctly matched dGTP across from a templating rC with a *k*~pol~ of 1.05 s^−1^ and a *K*~d~ for the incoming dGTP of 18.1 μM ([Figure 3A,D](#fig3){ref-type="fig"}). Both of these values are comparable to other non-replicative DNA polymerases and the TERT K~M~ values obtained by steady-state kinetics ([@bib9]; [@bib14]). We further probed the role of *tc*TERT active site residues R194 and Q308 because their role during catalysis is not clear from the structures alone and both residues protrude into the nucleotide binding pocket ([Figure 1F](#fig1){ref-type="fig"} and [Supplementary file 1](#supp1){ref-type="supplementary-material"}, Table 1a). For TERT R194A, the *k*~pol~ decreased by 28-fold to 0.0369 s^−1^, and the *K*~d~ for dGTP increased \~5 fold to 93 μM ([Figure 3---figure supplement 2A,C](#fig3s2){ref-type="fig"}). With the Q308A variant, the *k*~pol~ decreased \~60 fold to 0.30 s^−1^ and the *K*~d~ for dGTP increased \~2 fold to 45 μM ([Figure 3---figure supplement 2B,D](#fig3s2){ref-type="fig"}). Therefore, R194 and Q308 primarily play a role in the chemistry step rather than the nucleotide binding. As the *h*TERT homolog to R194 (R631, [Supplementary file 1](#supp1){ref-type="supplementary-material"}, Table 1a) is implicated in IPF, we infer that mutations at R631 likely reduce *h*TERT's *k*~pol~, contributing to IPF pathologies ([@bib2]; [@bib17]).

![TERT fidelity and sugar discrimination.\
(**A**) Pre-steady-state kinetics of WT tcTERT inserting dGTP opposite rC. Data was fit to [Equation 1](#equ1){ref-type="disp-formula"} ([Supplementary file 3](#supp3){ref-type="supplementary-material"}, Table 3a and b). Error bars represent the standard deviation of the mean. These experiments were also performed with WT tcTERT inserting dATP across from rC (**B**) and rGTP across from rC (**C**). Replots of the data and fits to [Equation 2](#equ2){ref-type="disp-formula"} were performed for (**D**) dGTP across from rC, (**E**) dATP across from rC, and (**F**) rGTP across from rC. (**G**) A comparison of TERT nucleobase fidelity (red line) compared to other DNA polymerase families. (**H**) TERT's rNTP discrimination rates (red line) compared to select DNA polymerases is shown ([@bib10]; [@bib33]).](elife-55438-fig3){#fig3}

During telomeric extension, telomerase must select between a variety of nucleic acid substrates in order to properly maintain telomeric integrity. To probe the fidelity of telomerase, we applied pre-steady-state kinetics, assessing the efficiency with which TERT inserts nucleotides during telomeric elongation. Two separate types of nucleotide selection were examined: (1) the selection of a matched dGTP over a mismatched dATP, and (2) the selection of a matched deoxyribonucletide triphosphate (dNTP) over a matched rNTP ([Figure 3B and C](#fig3){ref-type="fig"}, [Supplementary file 3](#supp3){ref-type="supplementary-material"}, Table 3a and b). We observed that for the insertion of dATP opposite a templating rC, the catalytic efficiency starkly decreased compared to dGTP insertion, both at the nucleotide binding and chemistry step. For the mismatched insertion, the *k*~pol~ decreased 129-fold to 0.0081 s^−1^ and the *K*~d~ increased 76-fold to 1.3 mM ([Figure 3E](#fig3){ref-type="fig"}). The resulting catalytic efficiencies (*k*~pol~/*K*~d~) for a matched versus mismatched nucleotide insertion indicate telomerase will insert the wrong nucleotide \~1 in 10,000 nucleotide insertion events. This places telomerase at a moderate fidelity of base selection compared to other DNA polymerases ([Figure 3G](#fig3){ref-type="fig"}). For rNTP discrimination, the *k*~pol~ for inserting a rGTP decreased 281-fold to 0.0037 s^−1^ and the *K*~d~ increased 49-fold to 0.89 mM ([Figure 3F](#fig3){ref-type="fig"}). This results in a nearly 14,000-fold decrease in the catalytic efficiency for the insertion of a rNTP compared to a dNTP (i.e. sugar discrimination, [Figure 3H](#fig3){ref-type="fig"}). Because the cellular concentrations of rNTPs are around 50-fold higher on average than dNTPs, this sugar discrimination indicates telomerase will insert a rNTP \~1 in 280 insertion events in a cellular context (see discussion) ([@bib57]).

The steric gate of telomerase {#s2-5}
-----------------------------

The high cellular concentration of rNTPs has resulted in most DNA polymerases evolving a structurally conserved active site residue which provides sugar discrimination by reducing the rate of rNTP insertion ([@bib10]; [@bib12]; [@bib41]). These residues are termed 'steric gates' because they clash with the 2'-OH of the incoming rNTP. Throughout the TERT catalytic cycle, we observed that Y256 rests in the minor groove of the DNA and is in position to clash with the 2'-OH of an incoming rNTP ([Figure 2E](#fig2){ref-type="fig"}). Therefore, we hypothesized this residue to be the steric gate in telomerase. To test this hypothesis, we performed pre-steady-state kinetics of rNTP insertion with the Y256A variant of TERT ([Figure 4A,B](#fig4){ref-type="fig"}). Compared to WT TERT, the insertion of a matched rGTP by Y256A showed a 1,490-fold increase in *k*~pol~ to 5.5 s^−1^ and a 12-fold decrease in *K*~d~ to 73 μM ([Figure 4C](#fig4){ref-type="fig"}). The results for TERT Y256A inserting a matched dGTP were similar to that of the rGTP, with a *k*~pol~ and *K*~d~ of 6.6 s^−1^ and 74 μM, respectively ([Figure 4D](#fig4){ref-type="fig"}). Thus, the sugar selectivity of TERT dropped from 14,000-fold between rGTP and dGTP for WT TERT to less than 2-fold for the Y256A TERT variant ([Figure 4E](#fig4){ref-type="fig"}). In other words, a single Y256A substitution increased rGTP insertion efficiency by 18,000-fold, abolishing almost all sugar discrimination. In a cellular environment, where rNTPs are at much higher concentrations than dNTPs, WT TERT would insert rGTP over 100-fold times less efficiently than dGTP. In contrast, TERT Y256A under cellular conditions would insert rGTP 77-fold times more efficiently than dGTP ([Figure 4F](#fig4){ref-type="fig"}; [@bib57]).

![The steric gate of TERT prevents insertion of rNTPs.\
Pre-steady-state kinetics of tcTERT with its steric gate removed (i.e. Y256A) for both (**A**) rGTP insertion and (**B**) dGTP insertion ([Supplementary file 3](#supp3){ref-type="supplementary-material"}, Table 3a). Error bars represent standard deviation of the mean. These graphs were replotted and fit to [Equation 2](#equ2){ref-type="disp-formula"} for (**C**) tcTERT Y256A inserting rGTP and (**D**) tcTERT Y256A inserting dGTP (**E**) A comparison of catalytic efficiencies (kpol/Kd) of both WT TERT and TERT Y256A for the insertion of dGTP (green) versus rGTP (red). (**F**) A comparison of TERT efficiencies adjusted for cellular nucleotide concentrations. (**G**) The prenucleotide binary complex of TERT Y256A (green) overlaid with the WT TERT prenucleotide binary complex structure (yellow). (**H, I**) The active site pocket of TERT Y256A, with DNA (white), RNA (purple), catalytic residues (blue), and nucleoside coordinating residues (cyan) shown. (**J**) The closest contacts to the C2 position of dGpCpp from the ternary structure (aligned and shown with yellow and green sticks) compared to Y256A tcTERT (cyan).](elife-55438-fig4){#fig4}

We next verified that this ablation in sugar discrimination was due to specific changes in the TERT active site rather than global rearrangements of the enzyme. To test for structural rearrangements, we crystallized the pre-nucleotide binary state of TERT Y256A (state A~6~), and saw minimal structural differences compared to the WT protein ([Figure 4G--J](#fig4){ref-type="fig"}). The position of the primer terminus was not changed, and catalytic residues D251, D343, and D344 were in position to catalyze the nucleotidyl transferase reaction ([Figure 4H](#fig4){ref-type="fig"}). Upon closer examination of the active site pocket, the substitution of Y256 with alanine resulted in a more open nucleotide binding pocket ([Figure 4H and I](#fig4){ref-type="fig"}). The distance from the C2 carbon of the dGpCpp to residue 256 shifted from 3.3 Å in WT TERT to 5.7 Å in TERT Y256A, showing that the TERT Y256A has much more room to accommodate the 2'-OH ([Figure 4J](#fig4){ref-type="fig"}). Taken as a whole, these results indicate Y256 clashes with the 2'-OH of rNTPs to provide sugar discrimination and is the steric gate in telomerase.

To determine if human telomerase uses a similar mechanism to discriminate against rNTP insertion, we implemented human telomerase activity assays ([@bib60]). In these assays, 1.5 telomeric repeats with the sequence TTAGGGTTAG were incubated with 50 µM of either all four dNTPs or all four rNTPs and purified 3xFLAG tagged human telomerase overexpressed with hTR. We performed these tests with both WT telomerase and a telomerase Y717A variant, which is the homologous residue to *tc*TERT Y256. WT telomerase showed robust primer extension in the presence of dNTPs, with \~10% of the primer extended into product over the course of 30 min ([Figure 5A,B](#fig5){ref-type="fig"}). Similarly, with all four dNTPs, the Y717A variant reached \~7% primer extension in the same amount of time ([Figure 5A,B](#fig5){ref-type="fig"}). In contrast, when we incubated WT telomerase with all four rNTPs rather than dNTPs, we observed very low (\<1%) primer extension after 30 min, suggesting that human telomerase discriminates against rNTPs, similar to *tc*TERT ([Figure 5C,D](#fig5){ref-type="fig"}). When we performed the same telomeric extension assay with the steric gate variant (Y717A), we observed that the primer extension was increased 3-fold compared to WT *h*TERT in the presence of rNTPs ([Figure 5C,D](#fig5){ref-type="fig"}). These results indicate the conserved residue Y717 in *h*TERT ([Supplementary file 1](#supp1){ref-type="supplementary-material"}, Table 1a) is the steric gate in human telomerase. Interestingly, in both WT and Y717A telomerase, minimal insertion past the first telomeric repeat was observed, which suggests the presence of rNTPs in telomere strands may inhibit the telomerase translocation step ([Figure 5C](#fig5){ref-type="fig"}).

![The steric gate of human telomerase.\
(**A**) Timecourse of primer extension with all four dNTPs by WT (left) and Y717A (right) human telomerase. (**B**) Quantification of percent primer extension, with WT shown as a blue line and the Y717A mutant shown in red. (**C**) Timecourse of primer extension with all four rNTPs for WT telomerase (left) and Y717A telomerase (right). (**D**) Results from the gel in panel C, quantified with the mutant telomerase shown in red and WT telomerase shown in blue. (**E**) Primer extension from both WT (left) and Y717A telomerase. Each lane contains either all four dNTPs, or three dNTP and one dNTP marked in red. (**F**) A close-up view of the first two telomeric repeats from selected lanes in panel E. rNTPs present in the mix are shown in red. Quantifications of each band in terms of percent product are also shown and labeled by the position of the telomerase templating base. The base marked by an asterisk is complementary to the rNTP in the solution. Error bars represent standard deviations of four biological replicates.](elife-55438-fig5){#fig5}

We next assessed if more subtle alterations in the nucleotide mixture would also cause inhibition of telomerase extension. By substituting one rNTP into the nucleotide mix at a time, we could determine the effects of inserting one, two, or three rNTPs inserted per repeat (with rATP, rUTP, and rGTP, respectively). In each case, telomerase processivity was reduced, with no bands evident past the second telomeric repeat ([Figure 5E](#fig5){ref-type="fig"}). The inhibitory effect seemed to depend on the number of rNTPs inserted per repeat, with rGTP presence showing the greatest inhibition. For the steric gate Y717A mutant telomerase, the effect of rNTPs on telomerase's processivity were much less pronounced. In the most extreme case of three rNTPs present per repeat, extension products are evident well into the second repeat, in contrast to the WT telomerase which had almost no insertion events ([Figure 5E](#fig5){ref-type="fig"}). We hypothesize that the rGTP insertion drastically inhibits WT telomerase because the first two insertions in the repeat are templated by rC. Therefore, the first event would need to be a rNTP insertion, followed by another rNTP insertion from a potentially unstable primer terminus. We are unable to decipher if inhibitory effects are due to the number of ribonucleotides per repeat, sequence-dependent inhibition, or a combination of both. In contrast to rGTP, telomerase is able to incorporate multiple repeats when rATP is present, albeit at a reduced efficiency compared to dNTPs ([Figure 5E](#fig5){ref-type="fig"}).

Within these primer extension activity assays, the effects of rNTP insertions can also be observed at the single nucleotide level. For rATP insertion with WT telomerase, we observed a buildup in substrates one nucleotide shorter than where the rNTP insertion would occur, composing \~60% of the total product formation ([Figure 5F](#fig5){ref-type="fig"}). This could be explained by the poor catalytic efficiency of telomerase for rATP insertion causing the enzyme to stall directly before the rATP insertion event. In contrast to the WT telomerase, the Y717A variant did not stall at the rATP insertion event. Interestingly, rNTPs inhibited translocation in both Y717A and WT telomerase, implying that telomerase possesses rNTP discrimination mechanisms beyond the level of single nucleotide incorporations ([Figure 5E,F](#fig5){ref-type="fig"}). The agreement between the results of the *tc*TERT and *h*TERT points towards a universal mechanism of sugar discrimination by any telomerase homolog with a tyrosine in this conserved position ([Supplementary file 1](#supp1){ref-type="supplementary-material"}, Table 1a).

Discussion {#s3}
==========

Telomerase's catalytic cycle and fidelity {#s3-1}
-----------------------------------------

In this study, we characterized each step of the TERT catalytic cycle for single nucleotide insertion. We found that, in terms of global protein structure, minimal rearrangement is required to proceed through the catalytic cycle. This lack of rearrangement contrasts many other DNA polymerases and even HIV RT, which have been shown to undergo global shifts from an 'open' to a 'closed' state upon nucleotide binding ([@bib18]; [@bib48]; [@bib51]). Although it is unknown why the TERT catalytic core does not open and close, it may be because other complexities necessary for telomerase function limit the opening and closing from occurring, including the translocation step during repeat addition or the extensive interaction with its RNA component. Within the active site, we observed residues that encompass a cavity for the incoming nucleotide prior to binding, which then adjust to coordinate the incoming nucleotide after binding, and continue to stabilize the newly inserted base after its insertion in the product state. Many of the active site residues involved in carrying out the catalytic cycle are in similar positions as other DNA polymerases; a triad of three carboxylate containing residues such as D251, D343, and D344 in *tc*TERT is conserved in many DNA polymerases ([@bib56]). Interestingly, R194 and Q308 are in a similar structural location to R61 and Q38 of human DNA polymerase η, and both have been shown to be important in its catalytic cycle ([@bib6]).

Our structural snapshots were complemented by kinetic studies, allowing us to understand how telomerase chooses right from wrong nucleotides; that is, selecting canonical dNTPs with correct base pairing compared to noncanonical rNTPs or mismatched base pairing ([Figure 6A](#fig6){ref-type="fig"}). Our experiments were carried out specifically with a single dGTP insertion using a 4 nucleotide overhang RNA template. While telomerase has been shown to exhibit moderate base and position-specific effects, our results indicate that the telomerase catalytic core generally exhibits moderate base selection fidelity, similar to that of X-family polymerases involved in DNA repair ([@bib14]; [@bib33]). Based on our kinetic values, we predict that telomerase inserts \~ 1 mismatch per each 10 kb of telomere extension. Because telomerase does not have a proofreading domain, misinsertions created by telomerase will remain as ssDNA during telomere elongation. Upon replication of the complementary strands by a DNA polymerase, the base that was a mismatch (in the context of telomerase) will become a matched base pair, and will not be a substrate for mismatch repair. Therefore, our fidelity measurement is predictive of cellular error rates in telomeric sequences. Accordingly, our predicted error rate agrees with telomeric error rates observed using telomere sequencing ([@bib31]). While the downstream consequences of telomeric mismatches have not been studied in a biological context to our knowledge, they likely would disrupt G-quadruplex stability and inhibit shelterin protein binding, as both of these phenomena are dependent on DNA sequence ([Figure 6B](#fig6){ref-type="fig"}; [@bib11]; [@bib16]).

![A model for how telomerase preserves telomeric integrity and biological implications.\
(**A**) The telomerase catalytic cycle, with matched dNTP (green), mismatched dNTPs (orange), and matched rNTPs (red). For each nucleotide path, kinetic parameters are labeled for each step and the insertion probability. (**B**) Downstream consequences of mismatch insertion by telomerase may include evasion of mismatch repair, reduced binding affinity for shelterin proteins, and altered stability of telomeric G quadruplexes. (**C**) Eventual consequences of rNTP insertion by telomerase. After insertion into telomeres, ribonucleotides could cause harsh consequences via hydrolysis, or disrupting telomere capping and stability. Ribonucleotides may also be removed by ribonucleotide excision repair.](elife-55438-fig6){#fig6}

Telomeric ribonucleotides {#s3-2}
-------------------------

DNA polymerases insert millions of rNTPs into the genome during replication, because of a large disparity in nucleotide concentrations (rNTPs are \~50 fold more abundant in cells than dNTPs) ([@bib57]). Telomerase also must select against this disparity; although telomerase is canonically thought to elongate telomeres with only dNTPs, our kinetics imply this is not the case. Instead, we predict that for every 10 kb of telomere extension, telomerase inserts \~ 40 rNTPs, which represents selectivity comparable to DNA polymerase β and DNA polymerase δ ([@bib10]; [@bib12]; [@bib41]). However, it is unknown whether ribonucleotides persist in telomeres, their biological consequences, and if they are addressed with ribonucleotide excision repair (RER), similar to other genomic ribonucleotides ([@bib53]). In our experiments with human telomerase, we found that even with increased rates of ribonucleotide insertion at the single nucleotide insertion level, telomere elongation was reduced via an inhibition of the translocation step ([Figure 5E,F](#fig5){ref-type="fig"}). This reduction was evident even with a single rNTP present in a telomeric repeat. Furthermore, previous studies have found telomeric substrates containing ribonucleotides can prevent or reduce extension of the first repeat depending on the number and position of ribonucleotides present in the DNA template ([@bib15]). It is possible that telomerase pauses after inserting ribonucleotides to provide an opportunity for an extrinsic proofreader or RER to remove the ribonucleotide before continuing telomeric elongation. Telomerase has previously been observed to halt telomeric extension after the insertion of other noncanonical nucleotides, particularly in the case of 8-oxodeoxyguanine triphosphate (8-oxodGTP) insertion ([@bib21]). Therefore, telomerase may stall on noncanonical nucleotides, such as 8-oxodGTP, for similar proofreading reasons.

Telomerase discrimination against rNTP insertion is important because ribonucleotides can cause multiple downstream problems for telomeric stability. These problems can arise from both the direct reduction of telomere length and from altering telomere structure. Because RNA is more vulnerable to hydrolysis than DNA, inserted ribonucleotides are more likely to hydrolyze, which would cause a telomeric single strand break ([@bib4]; [@bib16]; [@bib32]). If the strand break occurred before the complementary strand of the telomere was copied and ligated to the genome, the elongating single strand would be released, and the entire telomere elongation process would need to be restarted ([Figure 6C](#fig6){ref-type="fig"}). Alternately, the inserted ribonucleotide may not hydrolyze, but instead persist within telomeres. The continued presence of ribonucleotides in telomeres may cause several structural aberrations, including altering G-quadruplex stability and disrupting shelterin protein binding ([@bib20]; [@bib43]). If shelterin proteins are not able to bind to telomeres, telomere ends may be recognized as DNA damage, activating double strand break repair and causing disastrous biological consequences.

Subtle alterations to the telomeric nucleotides have previously been shown to cause telomeric disruption in a cellular context ([@bib21]; [@bib34]; [@bib55]). Even changes of only one atom in a nucleotide, including replacing an oxygen of a guanine with a sulfur to form therapeutic 6-thioguanine nucleotides or the adduction of an extra oxygen onto guanine to form 8-oxoguanine nucleotides, have significant biological consequences in the context of telomerase. Therefore, in order to prevent this telomeric disruption, the telomerase active site appears to have evolved a high degree of stringency towards noncanonical nucleotides, including both rNTPs and mismatched dNTPs. This stringency was evident by the reduced telomere elongation efficiency with every variant tested; other mutations could also be identified with this system that show increases in telomere elongation efficiency. Our structural characterization of the telomerase catalytic cycle allowed us to efficiently modify the stringent active site of telomerase, generating a human telomerase variant that readily inserts rNTPs. The applications shown here highlight the potential of combining model TERTs with complementary human telomerase studies to further probe the telomerase catalytic mechanism and screen future telomerase-targeting therapeutics.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                                    Designation                                                       Source or\                    Identifiers                                                          Additional\
  (species) or\                                                                                                      reference                                                                                          information
  resource                                                                                                                                                                                                              
  ------------------------------------------------ ----------------------------------------------------------------- ----------------------------- -------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------
  Gene (*Tribolium castaneum*)                     tcTERT                                                            GenScript                                                                                          

  Gene(*Homo sapiens)*                             hTR                                                               Gift from Dr. Tom Cech                                                                             

  Gene\                                            hTERT                                                             Gift from Dr. Tom Cech                                                                             
  (*Homo sapiens)*                                                                                                                                                                                                      

  Strain, strain background (*Escherichia coli)*   One Shot BL21(DE3)pLysS Chemically Competent *E. coli*            Invitrogen                    Cat\# C606010                                                        

  Strain, strain background (*Escherichia coli)*   One Shot TOP10 Chemically Competent *E. coli*                     Invitrogen                    Cat\# C606010                                                        

  Cell line (*Homo sapiens*)                       HEK 293 T Cells, female                                           ATCC                          RRID:[CVCL_0063](https://scicrunch.org/resolver/CVCL_0063)           Cells were acquired from ATCC, and have not since been tested for mycoplasma, as they were used for protein generation not biological assays

  Transfected construct (*Homo sapiens*)           pSUPER-hTR                                                        Gift from Dr. Tom Cech        N/A                                                                  

  Transfected construct (*Homo sapiens)*           pVan107 3X FLAG hTERT                                             Gift from Dr. Tom Cech        N/A                                                                  

  Recombinant DNA reagent                          pET-28a(+) with *Tribolium* castaneum TERT                        Genscript                     N/A                                                                  

  Sequence-based reagent                           Primer for telomerase activity assays                             IDT                           N/A                                                                  5'-GGTCAGGTCAGGTCA-3'

  Sequence-based reagent                           RNA template for *tc*TERT kinetics                                IDT                           N/A                                                                  5'-rCrUrGrArCrCrUrGACCUGACC-3'

  Sequence-based reagent                           DNA primer for *tc*TERT kinetics                                  IDT                           N/A                                                                  5'-/6-FAM/CCAGCCAGGTCAG-3'

  Sequence-based reagent                           RNA template\                                                     IDT                           N/A                                                                  5'- rUrGrArCrCrUrGrArCrCrUrGrG\
                                                   for *tc*TERT crystallogarphy                                                                                                                                         rCrUrGrG-3'

  Sequence-based reagent                           DNA primer for *tc*TERT crystallogarphy                           IDT                           N/A                                                                  5\'-GGTTAGGGTTAGGGTTAG-3\'

  Peptide, recombinant protein                     T4 polynucleotide kinase                                          NEB                           Cat\# M0201S                                                         

  Peptide, recombinant protein                     3X FLAG Peptide                                                   Sigma Aldrich                 Cat\# F4799-4MG                                                      

  Chemical compound, drug                          2\'-deoxyguanosine-5\'-\[(α,β)-methyleno\]triphosphate (dGpCpp)   Jena Biosciences              Cat\# NU-431S                                                        

  Chemical compound, drug                          γ−32P ATP                                                         Perkin-Elmer                  Cat\# BLU002Z250UC                                                   

  Chemical compound, drug                          2-methyl-2,4-pentanediol                                          Hampton Research              Cat\# HR2-627                                                        

  Software, algorithm                              COOT                                                              [@bib19]                      <https://www2.mrc-lmb.cam.ac.uk/personal/pemsley/coot/>              RRID:[SCR_014222](https://scicrunch.org/resolver/SCR_014222)

  Software, algorithm                              Phenix                                                            [@bib1]                       <https://www.phenix-online.org/>                                     RRID:[SCR_014224](https://scicrunch.org/resolver/SCR_014224)

  Software, algorithm                              XDS                                                               [@bib29]                      <http://xds.mpimf-heidelberg.mpg.de/>                                RRID:[SCR_015652](https://scicrunch.org/resolver/SCR_015652)

  Software, algorithm                              MolProbity                                                        [@bib13]                      <http://molprobity.biochem.duke.edu/>                                RRID:[SCR_014226](https://scicrunch.org/resolver/SCR_014226)

  Software, algorithm                              ImageJ                                                            [@bib52]                      <https://imagej.nih.gov/ij/>                                         RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)

  Software, algorithm                              Kaleidagraph                                                      Synergy Software              <http://www.synergy.com/wordpress_650164087/kaleidagraph/>           RRID:[SCR_014980](https://scicrunch.org/resolver/SCR_014980)

  Software, algorithm                              ImageQuant TL v8.1                                                GE Healthcare Life Sciences   [http://www.gelifesciences.](http://www.gelifesciences.com/en/us)\   RRID:[SCR_014246](https://scicrunch.org/resolver/SCR_014246)
                                                                                                                                                   [com/en/us](http://www.gelifesciences.com/en/us)                     

  Software, algorithm                              PyMol                                                             Schrödinger LLC               [https://pymol.](https://pymol.org/2/)\                              RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305)
                                                                                                                                                   [org/2/](https://pymol.org/2/)                                       

  Other                                            Large scale expresion (LEX-48) bioreactor                         Epiphyte                      <https://www.epiphyte3.com/LEX>                                      

  Other                                            HisTrap HP 5 mL column                                            GE healthcare Life Sciences   Cat\# 17524801                                                       

  Other                                            POROS HS strong cation ion exchange resin                         Thermo scientific             Cat\# 1335906                                                        

  Other                                            G-25 spin columns                                                 GE Healthcare Life Sciences   Cat \#27532501                                                       

  Other                                            Sephacryl 16/60 S-200 HR Size Exclusion Chromatography column     GE Healthcare Life Sciences   Cat \# 17116601                                                      

  Other                                            ANTI-FLAG M2 affinity gel agarose beads                           Sigma Aldrich                 Cat \#A2220                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Nucleic acid sequences {#s4-1}
----------------------

To generate crystal structures of the TERT catalytic cycle, the following DNA sequences were utilized for all crystallization experiments: DNA primer of 5'-GGTCAGGTCAGGTCA-3' and the RNA template sequence 5'-rCrUrGrArCrCrUrGACCUGACC-3'. For kinetic studies, we utilized a DNA primer with a 5' label of 6-carboxyfluorescein (6-FAM), and the DNA sequence of 5'- CCAGCCAGGTCAG-3'. The RNA template used in kinetic reactions contained the sequence 5'- rUrGrArCrCrUrGrArCrCrUrGrGrCrUrGrG-3' and was not labeled. In each case, the oligonucleotides were resuspended in molecular biology grade water, and the concentration was calculated from their absorbance at 260 nm as measured on a NanoDrop microvolume spectrophotometer. Nucleic acid substrates for crystallography were annealed at an equimolar ratio, but nucleic acid substrates for our kinetic studies were annealed at a 1:1.2 molar ratio of labeled to unlabeled primer. We used a thermocycler to anneal all nucleic acid substrates, heating them to 90°C for 2 min before cooling to 4°C at a rate of 0.1°C per second.

Expression and purification of *tc*TERT {#s4-2}
---------------------------------------

We used previously published methods for *tc*TERT expression and purification, but implemented several modifications ([@bib23]). Briefly, we grew *tc*TERT in BL-21(DE3)pLysS cells using an Epiphyte3 LEX bioreactor at 37°C until they reached an OD600 of 0.6--0.8, after which the temperature was dropped to 30°C for 4--5 hr of protein production. Cells were harvested via centrifugation at 4000 x g until lysis. For TERT purification, we used buffers containing 0.75 M KCl and 10% glycerol for the capture step on Ni-NTA columns (GE Healthcare), and then further purified our sample with cation exchange on a POROS HS column (Thermo Fisher), using a salt gradient of 0.5 M KCl to 1.5 M KCl. Then, we cleaved the hexahistadine tag with Tobacco etch virus protease before purifying the cut tag from the protein with another run on our Ni-NTA columns. Finally, we used a slightly different buffer for the our size exclusion chromatography (Sephacryl S-200 16/60, GE Helathcare), containing 50 mM Tris-HCl, pH 7.5, 10% glycerol, 0.8 M KCl and 1 mM Tris(2-carboxyethyl)phosphine (TCEP). Resultant *tc*TERT was concentrated down to 18 mg mL^−1^ prior to crystallography, and stored at 4°C ([@bib23]).

Crystallization of *tc*TERT {#s4-3}
---------------------------

Prior to crystallization, we complexed *tc*TERT with its nucleic acid substrate by mixing them at a 1:1.2 ratio of protein to DNA. To increase protein solubility, we included 520 mM KCl when preparing to mix *tc*TERT with its nucleic acid substrate. We then used sitting drop vapor diffusion to grow binary complex crystals in conditions containing 11% isopropanol, 0.1 M KCl, 25 mM MgCl~2~, and 50 mM sodium cacodylate pH 6.5. Volume ratios for the optimal crystal growth were optimized to 2.3 µL *tc*TERT binary complex crystals + 1.7 µL of our crystallization condition, to make 4 µL total. For the ternary complex crystals, we used the same conditions, but included 0.69 mM dGpCpp (Jena Biosciences), the next matched incoming nucleotide in the sequence. Finally, for the product complex, we formed a DNA strand one nucleotide longer by incubating 2.5 mM dGTP with *tc*TERT and its nucleic acid substrate, allowing the reaction to occur at 22°C for 30 min prior to setting up crystallization drops. In all cases, crystals were transferred to a cryosolution containing 80% reservoir solution and 20% 2-methyl-2,4-pentanediol by volume before flash cooling them in liquid nitrogen.

Data collection and refinement {#s4-4}
------------------------------

All datasets were collected at a wavelength of 1.00 Å, using the 4.2.2 synchrotron beamline at the Advanced Light Source of the Ernest Orlando Lawrence Berkeley National Laboratory. Datasets were indexed and scaled using XDS (RRID:[SCR_015652](https://scicrunch.org/resolver/SCR_015652)) ([@bib29]; [@bib59]). Initial models were generated using molecular replacement in PHENIX (RRID:[SCR_014224](https://scicrunch.org/resolver/SCR_014224)), using a previously published *tc*TERT structure with an alternate substrate, PDB code 3KYL ([@bib1]; [@bib36]). After a solution was found, all DNA and RNA bases were built in the pre-nucleotide complex, and the resultant structure was then used for further molecular replacements other structures. Model building was accomplished with Coot (RRID:[SCR_014222](https://scicrunch.org/resolver/SCR_014222)) and validated with MolProbity (RRID:[SCR_014226](https://scicrunch.org/resolver/SCR_014226)) ([@bib13]; [@bib19]). For structures ≥ 3 Å resolution, both secondary structure restraints and torsional restraints from the prenucleotide binary structure were used to prevent overmodeling. All refinements were done using PHENIX, and figures were generated using PyMOL (RRID:[SCR_000305](https://scicrunch.org/resolver/SCR_000305), Schrödinger LLC). For each of the structures, Ramachandran analysis revealed a minimum of 100% of non-glycine residues occupied allowed regions and at least 93% occupied favored regions.

Pre-steady-state kinetic characterization of *tc*TERT {#s4-5}
-----------------------------------------------------

Pre-steady-state kinetic parameters of *tc*TERT were obtained using established pre-steady-state kinetics protocols for DNA polymerases, also known as single turnover kinetics ([@bib5]; [@bib46]). Briefly, we preincubated 2 μM *tc*TERT with 200 nM annealed DNA:RNA hybrid substrate, with a 6-FAM label on the 5' end of the DNA component. We then used a KinTek RQF-3 (a rapid quench-flow instrument) to mix equal ratios of the incoming nucleotide triphosphate of interest and 10 mM MgCl~2~ with the existing mix of *tc*TERT and its DNA:RNA hybrid substrate. Reactions were run at 37°C and quenched at various timepoints (ranging from 10 ms to 700 s) with 100 mM EDTA pH 7.5. In each case, the conditions used for each reaction were: 25 mM TRIS pH 7.5, 0.05 mg mL^−1^ Bovine Serum Albumin, 1 mM dithiothreitol, 10% glycerol, 200 mM KCl, 1 μM *tc*TERT, 100 nM annealed DNA:RNA hybrid substrate, and varying concentrations of the nucleotide triphosphate of interest. The samples were transferred to a DNA gel loading buffer, containing 100 mM EDTA, 80% deionized formamide, 0.25 mg ml^−1^ bromophenol blue and 0.25 mg ml^−1^ xylene cyanol. For the generation of data sets that had a minimum time point of 12 s or greater, a LabDoctor heating block was used in lieu of the KinTec RQF-3, and quenching was accomplished using a solution of DNA gel loading buffer. These mixes were then incubated at 95°C for 5 mins and loaded onto a 21% denaturing polyacrylamide gel. These gels were run at 700 V, 60 A, and 30 W at 30°C in order to separate the reaction product from its substrate.

Gels were scanned and imaged using a GE Typhoon FLA 9500 imager, and the ratios of product to substrate were quantified using ImageJ (RRID:[SCR_003070](https://scicrunch.org/resolver/SCR_003070)) ([@bib52]). Means and standard deviations were taken from at least three technical replicates were calculated and graphed using KaleidaGraph (RRID:[SCR_014980](https://scicrunch.org/resolver/SCR_014980)). Plots of product formation over time were fit to the exponential [Equation 1](#equ1){ref-type="disp-formula"} to determine k~obs~ values:$$\left\lbrack P \right\rbrack = A\left( 1 - e^{- k_{obs}t} \right)$$

\[P\] is the concentration of the product, A is the target engagement (amplitude), and t is the reaction time. After k~obs~ values were determined for multiple nucleotide triphosphate concentrations, the data was replotted to compare k~obs~ to concentration of nucleotide triphosphate, and fit to [Equation 2](#equ2){ref-type="disp-formula"}:$$k_{obs} = \frac{k_{pol}\left\lbrack NTP \right\rbrack}{K_{d} + \left\lbrack NTP \right\rbrack}$$*k*~pol~ represents the theoretical maximum value of *k*~obs~, and \[NTP\] represents the concentration of the nucleotide of interest.

Telomerase expression {#s4-6}
---------------------

HEK293T cells were used to overexpress hTR and 3 × FLAG tagged human telomerase reverse transcriptase (hTERT) genes in pSUPER-hTR and pVan107, respectively. Cells were grown to 90% confluency in Dulbecco's modified Eagle's medium (Gibco) supplemented with 10% High Quality FBS (Hyclone) and 1% penicillin-streptomycin (Corning) at 37°C and 5% CO2. Cells were transfected with 10 μg of pSUPER-hTR plasmid and 2.5 μg of pVan107 hTERT plasmid diluted in 625 μl of Opti-MEM (Gibco) using 25 μl of Lipofectamine 2000 (ThermoFisher) diluted in 625 μl of Opti-MEM. Cells were cultured for 48 hr post-transfection, and then were trypsinized and washed with phosphate-buffered saline and lysed in CHAPS lysis buffer buffer (10 mM Tris-HCl, 1 mM MgCl~2~, 1 mM EDTA, 0.5% CHAPS, 10% glycerol, 5 mM β-mercaptoethanol, 120 U RNasin Plus (Promega), 1 μg/ml each of pepstatin, aprotinin, leupeptin and chymostatin, and 1 mM AEBSF) for 30 min at 4°C. Cell lysate supernatant was then flash frozen and stored at −80°C.

Telomerase purification {#s4-7}
-----------------------

Telomerase was purified via the 3xFLAG tag on hTERT encoded pVan107 using ANTI-FLAG M2 affinity gel agarose beads (Sigma Aldrich), as described previously with some modification ([@bib21]). An 80 μL bead slurry (per T75 flask) was washed three times with 10 volumes of 1X human telomerase buffer in 30% glycerol with 1 min centrifugation steps at 3500 r.p.m. at 4°C. The bead slurry was added to the lysate and nutated for 4--6 hr at 4°C. The beads were harvest by 1 min centrifugation at 3500 r.p.m, and washed 3X with 1X human telomerase buffer with 30% glycerol. Telomerase was eluted from the beads using 2x the bead volume of 250 μg/mL 3X FLAG peptide (Sigma Aldrich) in 1X telomerase buffer with 150 mM KCl. The bead slurry was nutated for 30 min at 4°C. The eluted telomerase was collected using Mini Bio-Spin Chromatography columns (Bio-Rad). Samples were flash frozen and stored a −80°C.

32P-end-labeling of DNA primers {#s4-8}
-------------------------------

50 pmol of PAGE purified DNA primer GGTTAGGGTTAGGGTTAG (IDT) was labeled with γ−32P ATP (Perkin Elmer) using T4 polynucleotide kinase (NEB) in 1X PNK Buffer (70 mM Tris-HCl, pH 7.6, 10 mM MgCL2, 5 mM DTT) in a 20 uL reaction volume. The reaction was incubated for 1 hr at 37°C followed by heat inactivation at 65°C for 20 min. G-25 spin columns (GE Healthcare) were used to purify the end labeled primer.

Telomerase activity assay {#s4-9}
-------------------------

The telomerase assay was as previously described. Reactions contained 1x human telomerase buffer, 5 nM of 32P-end-labeled primer and 50 μM dNTP or rNTP mix as indicated in the figure legends. Each reaction was performed with four biological replicates. The reactions were started by the addition of 3 μL of immunopurified telomerase eluent, incubated at 37°C for a specified time course, then terminated with 2 μL of 0.5 mM EDTA and heat inactivated at 65°C for 20 min. An equal volume of loading buffer (94% formamide, 0.1 × Tris borate-EDTA \[TBE\], 0.1% bromophenol blue, 0.1% xylene cyanol) was added to the reaction eluent from the G-25 spin column. The samples were heat denatured for 10 min at 100°C and loaded onto a 14% denaturing acrylamide gel (7M urea, 1x TBE) and electrophoresed for 90 min at constant 38W. Samples were imaged using a Typhoon phosphorimager (GE Healthcare). Percent primer extension was quantitated using ImageQuant (RRID:[SCR_014246](https://scicrunch.org/resolver/SCR_014246)).

Crystallographic statistics {#s4-10}
---------------------------

Resolution of our crystal structures was determined using correlation coefficients (CC~1/2~), with the highest resolution shell containing a CC~1/2~ value of greater than 0.3 ([Supplementary file 2](#supp2){ref-type="supplementary-material"}, Table 2a). During refinement, the statistics of R~work~ and R~free~, as calculated by PHENIX, were used to identify a model's fit to electron density. See [Supplementary file 2](#supp2){ref-type="supplementary-material"}, Table 2a for more details of these parameters for each dataset.

Data resources {#s4-11}
--------------

Accession numbers for models reported are PDB: 6USO, 6USP, 6USQ, and 6USR.
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###### Table 1a.

The conservation and function of TERT active site residues. Table 1b. Telomerase architecture of five different TERTs, including *Homo sapiens, Tetrahymena thermophila,Saccharomyces cerevisiae* and *Tribolium castaneum*. Data from this table used from: ([@bib22]; [@bib23]; [@bib28]; [@bib40]; [@bib42]).

^1^TR = Telomerase RNA component

\*TEN = N terminal domain

\*TRBD = Telomerase RNA binding domain

\*RT = Reverse transcriptase domain

\*CTE = C terminal extension

\*IFD = Insertion in fingers domain

^2^ This IFD is truncated compared to other TERTs.

###### Table 2a.

Data collection and refinement statistics for *tc*TERT structures.

###### Table 3a.

Kinetic parameters and errors for *tc*TERT pre-steady-state kinetics of single nucleotide incorporation. Table 3b. Full kinetic parameters of each curve used to generate K~obs~ and target engagement values in *tc*TERT pre-steady-state kinetics

Data availability {#s7}
=================

Diffraction data have been deposited in PDB under the accession code 6USO, 6USP, 6USQ, and 6US.

The following datasets were generated:

FreudenthalBDSchaichMA2020Telomerase Reverse Transcriptase prenucleotide binary complex, TERT:DNARCSB Protein Data Bank6USO

FreudenthalBDSchaichMA2020Telomerase Reverse Transcriptase ternary complex, TERT:DNA:dGpCppRCSB Protein Data Bank6USR

FreudenthalBDSchaichMA2020Telomerase Reverse Transcriptase product complex, TERT:DNARCSB Protein Data Bank6USP

FreudenthalBDSchaichMAKhoangTH2020Telomerase Reverse Transcriptase binary complex with Y256A mutation, TERT:DNARCSB Protein Data Bank6USQ
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**Acceptance summary:**

The reviewers and the reviewing editor agreed that this work is significant because it is not known how telomerase selects the correct nucleotide for insertion into the telomeric repeat from a pool of nucleotide with various sugars and base pairing properties. This work is an important advance defining (at least in vitro) nucleotide selection by telomerase through the first high resolution crystal structures of *Tribolium castaneum* telomerase reverse transcriptase (TERT) throughout its catalytic cycle and characterization of the Tribolium and human TERT kinetics. The authors solved the three structures of Tribolium TERT in complex with a DNA/RNA duplex with 1 nucleotide (nt) overhang, the same duplex with a non-hydrolyzable analog of dGTP and a product DNA/RNA duplex. The most important new finding was that there is a steric gate that allows TERT to discriminate dNTPs from rNTPs. The authors show that this residue (Y717) serves similar functions in human telomerase.

**Decision letter after peer review:**

Thank you for submitting your article \"Mechanisms of nucleotide selection by telomerase\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Cynthia Wolberger as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

Summary:

The reviewers and the reviewing editor agreed that this work is significant because it is not known how telomerase selects the correct nucleotide for insertion into the telomeric repeat from a pool of nucleotide with various sugars and base pairing properties. This work is an important advance defining (at least in vitro) nucleotide selection by telomerase through the first high resolution crystal structures of *Triboliumcastaneum* telomerase reverse transcriptase (TERT) throughout its catalytic cycle and characterization of the Tribolium and human TERT kinetics. The authors solved the three structures of Tribolium TERT in complex with a DNA/RNA duplex with 1 nucleotide (nt) overhang, the same duplex with a non-hydrolyzable analog of dGTP and a product DNA/RNA duplex. The most novel finding was a steric gate which allows TERT to discriminate dNTPs from rNTPs and the authors show that this residue (Y717) serves similar functions in human telomerase.

The reviewers and the reviewing editor, however feel that there are insufficient discussion and comparison with other structural and biochemical work, especially in the light of similarity between these new reported structures and those published by Gillis et al., 2008 and Mitchell et al., 2010, with the product state being almost the same as that reported by Mitchell et al., 2010. There is also a question of state I designation that needs to be addressed experimentally.

Essential revisions:

Significant revisions that will require new experiments:

The main concern of the reviewers was related to \"state I\" designation. The authors chose a substrate where the RNA primer has just one 3\' nucleotide overhang, perhaps to prevent subsequent cycles of catalysis. But since *tc*TERT uses RNA primers with up to 6 nt overhang, it is conceivable that the template-TERT conformation, especially the RNA-interacting residues could be very different between 1 and 6 templating bases. In a natural telomerase RNP, the RNA template threads through the TERT ring. The reviewers questioned whether \"state I\" described in the paper with only 1 nt overhang truly represents state I. In the recent Tetrahymena EM structure at 4.8 Å (Jiang et al., Science 2018), a stretch of the locked-DNA substrate is bound to the RNA template, which may be more representative of state I in the cycle. For the main conclusions of this paper to be valid, the authors need to provide a new structure of state I with the 6 nt overhang RNA primer (preferred) or show that the structure they have behaves the same way as State I.

Other significant revisions:

1\) Wu et al., (EMBO 2017) extensively characterized how the DNA substrate is handled during each cycle of repeat synthesis and suggested a more detailed catalytic cycle than what is proposed in Figure 1 here. It involved partial duplex melting before the synthesis reaches the template 5\' end, allowing translocation to occur. It has also been shown that the kinetics of the addition of each nt within each telomeric repeat is not the same (Chen et al., 2018). So far the structures and kinetics have only been done with one single addition of dGTP in this work, which will be different for other nucleotides of the repeat. This point needs to be carefully addressed.

2\) The authors identified critical residues for the catalytic activity and fidelity, revealing similarities and differences with other DNA polymerases. This said, while Tribolium TERT provides a good model system for studying TERT structure, it lacks the TEN domain and a large part of the IFD, which have been shown to be crucial for TERT activity and processivity in human and Tetrahymena. This major difference and whether the kinetics observations can be generalized to other telomerases warrants a discussion.

3\) The Y717 steric gate is required for discriminating dNTPs from rNTPs, which is nicely shown in the human telomerase case. There is indeed a correlation between the number nucleotide in the repeat and the rate of incorporation. However, it is intriguing that the enzyme is still able to incorporate a couple of repeats with rATP. This suggests that in the human case the rATP in this position can be tolerated to some extent. Besides the sugar gate, could the base identity have some effects too?

4\) The description of critical residues surrounding RNA as well as incoming nucleotide is often too vague. More modeling or description is needed. For instance, how does R194 relocation/move between different state?

5\) Please provide details to those who are not familiar with *T. casteneum* telomerase such as the TERT and TR molecular weights and how they differ from human or mouse telomerase. Also the authors should elaborate more on the TR version for *T. casteneum*. We assume as readers that the authors could not co-crystalize with \"tcTR\" for similar reasons as the field is not able to crystalize human hTR + hTERT. Please provide some background on that (perhaps in the Introduction).

6\) It seems that the authors generated the RNA:DNA hybrid substrate prior to incubating with *tc*TERT. What was the reason for this? Could they incubate the RNA 16-mer with *tc*TERT to allow that complex to assemble and then add the 15-mer complimentary DNA substrate? Would they see the same results? Technically speaking the substrate for telomerase is the DNA (nucleotide or single stranded). The RNA is a part of the enzymatic complex.

7\) Subsection "Product complex". It makes sense that there are minimal rearrangements since it could be predicted that the majority of movement is in the RNA subunit of telomerase (which is missing in this model). However, a key question is to know how it stays on and translocates after a full hexameric repeat is added. The authors may want to review a recent paper (J. Biol. Chem., 294(30):11579-11588, 2019). This work provides a more macro look at the telomerase catalytic cycle that may provide some insights into the present studies.

8\) Please elaborate on the chemistry step vs nucleotide binding step.

9\) Subsection "The steric gate of telomerase" paragraph three. Please include the details of the telomerase used. Was a recombinant telomerase with 3xFLAG tag and overexpressed hTR used? This is important as we have now seen that the tags used for telomerase play a role for in-vitro and in-vivo activity.

10\) Figure 5C. If you generated a custom single-stranded substrate with dNTPs and rNTPs, would you even lose that first extension? Maybe an experiment like this will test the assumption that it \"may inhibit the telomerase translocation step.\"

11\) Subsection "The steric gate of telomerase" paragraph four. rGTP displayed the greatest inhibition. Is this because 3Gs are in the hexameric repeat or is this due to something else? Some discussion on this would be helpful.

12\) While all alterations resulted in reduction of telomere extension by telomerase, did any alterations tested enhance telomere extension (e.g. decreased pausing, improved processivity etc). This should be mentioned in the Discussion.

13\) Any evidence in the current series of experiment that the alterations of inserted ribonucleotides causes DNA damage or lack of shelterin protection. While this has been shown by others in cells using altered nucleotide insertion into telomeres, there are no cell-based studies in the present studies to confirm or progress much of the speculation in the Discussion since all experiments in the present studies use a somewhat artificial in vitro (test tube) approach. For example, do altered ribonucleotides persist in telomeres and is there any evidence that RER removes them? Also, what is the evidence that a single misinsertion every 10kb would prevent shelterin binding or disrupt G-quadruplex stability? Even with these concerns, the studies are important to help future studies confirm and extend these finding.

10.7554/eLife.55438.sa2

Author response

> Essential revisions:
>
> Significant revisions that will require new experiments:
>
> The main concern of the reviewers was related to \"state I\" designation. The authors chose a substrate where the RNA primer has just one 3\' nucleotide overhang, perhaps to prevent subsequent cycles of catalysis. But since tcTERT uses RNA primers with up to 6 nt overhang, it is conceivable that the template-TERT conformation, especially the RNA-interacting residues could be very different between 1 and 6 templating bases. In a natural telomerase RNP, the RNA template threads through the TERT ring. The reviewers questioned whether \"state I\" described in the paper with only 1 nt overhang truly represents state I. In the recent Tetrahymena EM structure at 4.8 Å (Jiang et al., Science 2018), a stretch of the locked-DNA substrate is bound to the RNA template, which may be more representative of state I in the cycle. For the main conclusions of this paper to be valid, the authors need to provide a new structure of state I with the 6 nt overhang RNA primer (preferred) or show that the structure they have behaves the same way as State I.

We would like to first apologize to the reviewers and reviewing editor for the confusion in regards to Figure 1A and specifically our nomenclature of "state I". This figure was generated with simplicity in mind and clearly this was a confusing error on our behalf. To address this error, we have done the following: (1) remade Figure 1A with distinct nomenclature for each step in the catalytic cycle; (2) made an additional supplemental figure (Figure 1---figure supplement 3) that describes all 18 steps during the telomerase catalytic cycle for one telomeric repeat addition; and (3) clearly indicated which structural state we are describing in the telomerase catalytic cycle for each reported structure. These changes are expanded upon below.

We wish to thank the reviewers for their suggestion of an additional structure, and agree that each overhang length from one to six will result in unique TERT structural states, with a combined 18 structures needed in total. To this end, we spent over a year aggressively screening \~70,000 crystallization conditions. This involved screening multiple TERT protein constructs and over 40 different nucleic acid substrates of various different overhang lengths, hairpins, and substrates with overhangs on both sides. Moreover, we also employed the resources and expertise of the KU Lawrence campus structural biology core to screen additional crystallization conditions and protein constructs to no avail. So far, the only nucleic acid substrate that has successfully yielded structural information was the one featured in this paper. Even after this initial hit was obtained, we spent months optimizing the condition, and had to screen through hundreds of crystals at the synchrotron Xray source to get the 2.5 Å resolution presented here. Therefore, even if we were able to immediately get an additional novel crystal hit, a new TERT structure could take upwards of a year to generate at an appreciable resolution. It is worth mentioning, prior to the lab closing down for COVID-19, we were actively working to obtain additional high-resolution structural snapshots with various substrates for follow-up studies and will continue this once the lab and synchrotron reopen as we feel novel structural snapshots at each step is a pressing question in the telomerase field.

Instead of obtaining a new crystal structure for the revised manuscript, we would like to emphasize that, although our structure has a one nucleotide gap instead of six, we feel it provides significant insight into the telomerase catalytic cycle at each step. This is because the pre-nucleotide bound category is visited 6 times (Figure 1A and Figure 1---figure supplement 3, steps A~1-6~) prior to the telomerase translocation step. In other words, although the templating RNA base shifts between each of the 6 insertion positions, the TERT active site must go through the general cycle of: free nucleotide binding pocket → nucleotide triphosphate bound within the active site → nucleotide insertion (i.e. product formation). In the initial submission, we had attempted to group all 18 structural states based on the components in the TERT active site, but in response to these peer reviews we have now clarified our catalytic cycle to explicitly include all 18 states (see Figure 1---figure supplement 3). Furthermore, we have changed the labeling scheme in the text to now identify our structural snapshots as states A~6,~ B~6~, and C~6~. In all other current structures of TERT (including Mitchell et al., 2010, and Jiang et al., 2018), the TERT active site is positioned at the primer terminus, with the last inserted nucleotide still in the nucleotide binding pocket, which are all members of the final product step of nucleotide addition or the "C" category of the structural states in Figure 1---figure supplement 3. We think this new labeling scheme highlights that we are presenting two new categories of structural states, "A" and "B". Furthermore, although structural information for category A and B structures are unknown (prenucleotide and ternary), we can compare our C category structure to the lower resolution cryo-EM structure of *Tetrahymena thermophila* telomerase (Jiang et al., 2018). The positions of key active site amino acids from *tt*TERT state C~3~ closely align with our state C~6~ (RMSD = 0.83, see [Author response image 1](#respfig1){ref-type="fig"}, Figure 1---figure supplement 3 for state designations). This structural agreement between different states and homologs implies that active site contacts are similar throughout all 6 overhang lengths.

![A comparison of ttTERT active site residues with *tc*TERT.\
A superposition of the *tc*TERT product structure active site (state C6, yellow) with the active site from the product structure from ttTERT (State C3, green, from Jiang et al., 2018, PDB code: 6D6V). Key active site amino acid residues including catalytic residues (in A), and nucleoside coordinating residues (B) align closely, exhibiting a Root Mean Squared Deviation (RMSD) of 0.83.](elife-55438-resp-fig1){#respfig1}

Finally, previous kinetic studies provide evidence that the structural states that we have presented in this manuscript are more representative of a typical telomerase catalytic cycle than structures of the first insertion event (which we had mistakenly called state I in the initial submission). In a recent *EMBO* paper (2018, Chen et al.), steady-state kinetics were performed for all six templating positions. In this study, it was shown that the K~M~ values for the incoming nucleotide vary by a maximum of \~30-fold depending on the registry position (i.e. overhang length). These values were 120 μM for the 6-nucleotide overhang, and 4, 31, and 5 μM for four, two, and single nucleotide overhangs, respectively. Of note, out of all six templating positions, the substrate with six templating bases exhibited altered kinetics compared to the other 5 positions. Thus, the structural snapshot we report here (one nucleotide overhang) is likely representative of a typical catalytic cycle (i.e. 15/18 structural states of A~2~ to C~6~, Figure 1---figure supplement 3) as compared to a six-nucleotide overhang that is representative of only 3/18 structural states.

In summary, we sincerely apologize for our error in the description of state I in the initial submission and have corrected this in the revised manuscript. While we would like to obtain a structure with a six nucleotide overhang, we are not confident this will be attainable and will likely require a follow-up study on all eighteen catalytic states. Although this structural information is not available, comparisons to TERT structures with a different overhang length ([Author response image 1](#respfig1){ref-type="fig"}) and the kinetics of various overhang lengths (performed in Chen et al., 2018) give us confidence that the catalytic cycle presented here represents a typical catalytic cycle for telomerase. Furthermore, the overall trends we describe in terms of fidelity, sugar selectivity, and nucleotide binding affinity are based on observed differences of up to four orders of magnitude and likely would not be altered by the moderate \~30-fold changes in K~M~ seen at different registry positions.

> Other significant revisions:
>
> 1\) Wu et al., (EMBO 2017) extensively characterized how the DNA substrate is handled during each cycle of repeat synthesis and suggested a more detailed catalytic cycle than what is proposed in Figure 1 here. It involved partial duplex melting before the synthesis reaches the template 5\' end, allowing translocation to occur. It has also been shown that the kinetics of the addition of each nt within each telomeric repeat is not the same (Chen et al., 2018). So far the structures and kinetics have only been done with one single addition of dGTP in this work, which will be different for other nucleotides of the repeat. This point needs to be carefully addressed.

We wish to thank the reviewers for highlighting the complexity of the catalytic cycle, and template position dependence of incoming nucleotides. Further clarification about both phenomena have been added to the manuscript text and also below for reference. Additionally, Figure 1 in the manuscript has been carefully updated to better clarify and address the details of the catalytic cycle.

"This core catalytic cycle repeats six times, until a new telomeric repeat is added (Figure 1A, state C~6~). All 18 telomerase states that are required to add one telomeric repeat are shown in Figure 1--- figure supplement 3 for reference. Importantly, as the telomerase approaches the end of its template, the DNA:RNA duplex at the 5' end begins to melt, enabling telomerase to either (1) translocate and anneal the RNA component to the newly extended telomeric repeat, thus allowing for additional repeat addition; or (2) dissociate from the telomeric DNA."

"Our experiments were carried out specifically with a single dGTP insertion using a 4 nucleotide overhang RNA template. While telomerase has been shown to exhibit moderate base and position-specific effects, our results indicate that the telomerase catalytic core generally exhibits moderate base selection fidelity, similar to that of X-family polymerases involved in DNA repair (Chen et al., 2018; McCulloch and Kunkel, 2008)."

> 2\) The authors identified critical residues for the catalytic activity and fidelity, revealing similarities and differences with other DNA polymerases. This said, while Tribolium TERT provides a good model system for studying TERT structure, it lacks the TEN domain and a large part of the IFD, which have been shown to be crucial for TERT activity and processivity in human and Tetrahymena. This major difference and whether the kinetics observations can be generalized to other telomerases warrants a discussion.

We carefully chose *Tribolium castaneum* TERT as a model TERT with full knowledge that it lacks both the TEN domain and a large part of the IFD, compared to hTERT. We agree and wish to thank the reviewers for suggesting that we explicitly acknowledge and discuss this important difference amongst TERTs. To address this, we have created a new table further entailing the differences between several different TERTs and added text discussing these crucial differences.

"Although TERTs have highly conserved active sites, there are significant changes in the domain architecture between human and *tc*TERT. These include *tc*TERT lacking the N-terminal (TEN) domain and missing a portion of the insertion in fingers domain (IFD) (Supplementary file 1---table 1B). These domains are essential for the activity of other telomerase homologs, and have been hypothesized to be particularly important for telomerase ratcheting during translocation (Steczkiewicz et al., 2011). Therefore, we kept our *tc*TERT kinetics within a single turnover (i.e. insertion) regime, and, wherever possible, complemented the kinetic results with human telomerase studies to characterize the catalytic cycle of telomerase."

> 3\) The Y717 steric gate is required for discriminating dNTPs from rNTPs, which is nicely shown in the human telomerase case. There is indeed a correlation between the number nucleotide in the repeat and the rate of incorporation. However, it is intriguing that the enzyme is still able to incorporate a couple of repeats with rATP. This suggests that in the human case the rATP in this position can be tolerated to some extent. Besides the sugar gate, could the base identity have some effects too?

We are grateful to the reviewers for commenting that base-identity could also play a role in ribonucleotide tolerance. We originally thought that the number of insertions per repeat was dominating this effect, but agree that base identity and position in the template could also influence ribonucleotide tolerance by telomerase. This is particularly interesting, as rATP is present at a much higher concentration than other ribonucleotides in the cell (Traut, 1994), so it would make sense that more rATPs would be inserted, and therefore need to be tolerated. These ideas have been included in the text.

"In the most extreme case of three rNTPs present per repeat, extension products are evident well into the second repeat, in contrast to the WT telomerase which had almost no insertion events (Figure 5E). We hypothesize that the rGTP insertion drastically inhibits WT telomerase because the first two insertions in the repeat are templated by rC. Therefore, the first event would need to be a rNTP insertion, followed by another rNTP insertion from a potentially unstable primer terminus. We are unable to decipher if inhibitory effects are due to the number of ribonucleotides per repeat, sequence-dependent inhibition, or a combination of both. In contrast to rGTP, telomerase is able to incorporate multiple repeats when rATP is present, albeit at a reduced efficiency compared to dNTPs (Figure 5E)."

> 4\) The description of critical residues surrounding RNA as well as incoming nucleotide is often too vague. More modeling or description is needed. For instance, how does R194 relocation/move between different state?

Thank you to the reviewers for this comment. We welcome a chance to expand a bit more on our structural results, and have added more descriptions throughout that section, including how R194's position and environment change throughout the catalytic cycle. Please see changes to the Results section.

> 5\) Please provide details to those who are not familiar with T. casteneum telomerase such as the TERT and TR molecular weights and how they differ from human or mouse telomerase. Also the authors should elaborate more on the TR version for T. casteneum. We assume as readers that the authors could not co-crystalize with \"tcTR\" for similar reasons as the field is not able to crystalize human hTR + hTERT. Please provide some background on that (perhaps in the Introduction).

We thank the reviewers for the opportunity to further clarify the differences between TERT homologs. As the TR component of telomerase creates flexibility and heterogeneity in the structure, the reviewers are correct that any telomerase holoenzyme with a TR component is a poor substrate for crystallography, which is why we used a truncated version of the TR. To address this (and point 2 above), we've created a supplemental table (Supplementary file 1---table 1B) entailing the differences in domain architecture and molecular weight between several TERTs from different species, in addition to altering the introductory text:

"...third, using a truncated version of the *T. castaneum* telomerase RNA component (TR), we can readily obtain sufficient quantities of isolated, active *tc*TERT for characterization of the telomerase catalytic cycle by pre-steady-state kinetics and X-ray crystallography (Gillis et al., 2008; Nguyen et al., 2018). Although TERTs have highly conserved active sites, there are significant changes in the domain architecture between human and *tc*TERT. These include *tc*TERT lacking the Nterminal (TEN) domain and missing a portion of the insertion in fingers domain (IFD) (Supplementary file 1---table 1B). These domains are essential for the activity of other telomerase homologs, and have been hypothesized to be particularly important for telomerase ratcheting during translocation (Steczkiewicz et al., 2011). Therefore, we kept our *tc*TERT kinetics within a single turnover (i.e. insertion) regime, and, wherever possible, complemented the kinetic results with human telomerase studies to characterize the catalytic cycle of telomerase."

> 6\) It seems that the authors generated the RNA:DNA hybrid substrate prior to incubating with tcTERT. What was the reason for this? Could they incubate the RNA 16-mer with tcTERT to allow that complex to assemble and then add the 15-mer complimentary DNA substrate? Would they see the same results? Technically speaking the substrate for telomerase is the DNA (nucleotide or single stranded). The RNA is a part of the enzymatic complex.

Thank you for the feedback on the generation of our TERT:RNA:DNA complex. We agree that in a biological context, the RNA component of telomerase is assembled as part of the enzymatic complex before it binds to DNA. Hence, for the human telomerase experiments, we assembled the RNA component with telomerase prior to running any of our human telomerase reactions. In our structural studies with *tc*TERT, we preincubated the RNA and DNA prior to the addition of TERT because a homogenous sample is vital for crystal formation. We hypothesize that mixing TERT with the RNA component prior to adding the DNA could result in excess free DNA strands or a TERT:RNA complex that isn't bound to the DNA, which could prevent crystal formation. Furthermore, when we compare the position of the RNA strand from our structure to that from a recent cryo-EM structure of telomerase holoenzyme (that was made by incubating TERT:RNA with the DNA strand, Jiang et al., 2018) the position of the RNA strand overlays well between the two structures within the active site of the enzyme ([Author response image 2](#respfig2){ref-type="fig"}). Therefore, we do not predict that changing the order of assembly greatly impacts the structure of the TERT:RNA:DNA complexes that are formed over the course of days in a crystallization solution.

![RNA used with *tc*TERT structures vs TR from *Tetrahymena thermophila*.\
A superposition of the RNA component from our product structure (yellow, state C6) and the recent cryo-EM structure of *T. thermophila* (green, state C3, Jiang et al., 2018, PDB code 6d6v). *tc*TERT protein is shown as gray ribbons for reference.](elife-55438-resp-fig2){#respfig2}

For our pre-steady-state kinetic regime, it is of utmost importance that the enzymatic complex is fully assembled prior to introducing the nucleotide triphosphates. This way, the rate limiting steps for catalysis are only the binding of the nucleotide and the subsequent enzymatic turnover; if we only incubated TERT with the RNA template, and then initiated the reaction by adding the DNA strand and the next incoming nucleotide, it is likely that at that point the rate limiting step would be the annealing of the two nucleic acid strands rather than nucleotide binding and subsequent insertion. Therefore, in these assays, we also needed to preincubate the duplex prior to starting the reaction.

> 7\) Subsection "Product complex". It makes sense that there are minimal rearrangements since it could be predicted that the majority of movement is in the RNA subunit of telomerase (which is missing in this model). However, a key question is to know how it stays on and translocates after a full hexameric repeat is added. The authors may want to review a recent paper (J. Biol. Chem., 294(30):11579-11588, 2019). This work provides a more macro look at the telomerase catalytic cycle that may provide some insights into the present studies.

Thank you for directing our attention to this recent publication; we agree that the macro look at the catalytic cycle is relevant to the present studies, and have made note of some of the key findings of this paper in our introduction of the catalytic cycle. As we see an inactivation of telomerase upon insertion of ribonucleotides, an outstanding question is whether the mechanism of inactivation is related to the catalysis-dependent inactivation observed in the Sayed et al. study. One possibility is that reactivation with iTAFs would increase translocation efficiency with noncanonical substrates. We do feel that these questions, although interesting, lie outside of the scope of the present manuscript.

"Importantly, as the telomerase approaches the end of its template, the DNA:RNA duplex at the 5' end begins to melt, enabling telomerase to either (1) translocate and anneal the RNA component to the newly extended telomeric repeat, thus allowing for additional repeat addition; or (2) dissociate from the telomeric DNA. The number of times that a single telomerase enzyme traverses this catalytic cycle is tightly regulated. It was recently shown telomerase becomes inactive after two repeats, but can be reactivated by the recently discovered intracellular telomerase-activating factors (iTAFs) (Sayed et al., 2019)."

> 8\) Please elaborate on the chemistry step vs nucleotide binding step.

We have elaborated on these two steps in context of the catalytic cycle for clarity:

"Next, the binary complex binds an incoming dNTP and samples for proper Watson-Crick base pairing to the RNA template (Figure 1A, state B~1~). The transition between these two states represents the nucleotide binding step, measured as a dissociation constant (K~d~). If the resulting ternary complex (TERT:DNA:dNTP) is in the proper orientation, TERT will catalyze the formation of a phosphodiester bond and extend the telomere by one nucleotide (Figure 1A, state C~1~). The transition between these two states is the chemistry step, and its theoretical maximum rate with saturating nucleotide concentration is described as k~pol~. Following insertion of the incoming nucleotide, telomerase will shift registry to align the active site with the next templating base (forming state A~2~)."

> 9\) Subsection "The steric gate of telomerase" paragraph three. Please include the details of the telomerase used. Was a recombinant telomerase with 3xFLAG tag and overexpressed hTR used? This is important as we have now seen that the tags used for telomerase play a role for in-vitro and in-vivo activity.

Yes, the telomerase used was a recombinant telomerase with 3xFLAG tag and overexpressed hTR (see below). For clarity on the construct used, more details of the methods were added to the Results section:

"In these assays, 1.5 telomeric repeats with the sequence TTAGGGTTAG were incubated with 50 µM of either all four dNTPs or all four rNTPs and purified 3xFLAG tagged human telomerase overexpressed with hTR."

> 10\) Figure 5C. If you generated a custom single-stranded substrate with dNTPs and rNTPs, would you even lose that first extension? Maybe an experiment like this will test the assumption that it \"may inhibit the telomerase translocation step.\"

How pre-existing ribonucleotides in a telomere strand might affect even the first extension of telomerase is a particularly interesting question. This type of question is something we became interested in during prior studies with modified nucleotides inserted into telomeres (Fouquerel et al., 2016). In the case of 8oxoguanine or 8-oxodGTP, pre-existing 8-oxoG in the telomere strand increased telomerase activity by disrupting G-quadruplex structures that prevented telomerase binding, whereas 8-oxodGTP that was inserted by telomerase inhibited the activity of telomerase. This example highlights the complexity of characterizing the effect of inserted non-canonical nucleotides vs pre-existing modified nucleotides in an annealed oligo.

In response to this question, we refer the reviewers to a publication that examined the impact of ribonucleotides in the template for telomerase (Collins and Greider, 1995, *EMBO*). Briefly, telomerase primer extension assays were performed using primers containing various amounts of ribonucleotides present in the primer strand (see Figure 6 in the referenced work). As predicted by the reviewers, in some cases, placing ribonucleotides in the primer strand inhibited even the first extension of telomerase. In other cases, such as the oligonucleotide that only had three ribonucleotides present (sequence: d(G~3~T~2~G)~2~G~3~r(U~2~G) ), telomerase extended the substrate with a reduced efficiency. We feel that the insights from these hybrid substrates better inform our interpretation of how ribonucleotides influence the mechanism of telomerase. Therefore, we added a reference to the work to better make our case that ribonucleotides inhibit telomerase translocation:

"This reduction was evident even with a single rNTP present in a telomeric repeat. Furthermore, previous studies have found telomeric substrates containing ribonucleotides can prevent or reduce extension of the first repeat depending on the number and position of ribonucleotides present in the DNA template (Collins and Greider, 1995)."

> 11\) Subsection "The steric gate of telomerase" paragraph four. rGTP displayed the greatest inhibition. Is this because 3Gs are in the hexameric repeat or is this due to something else? Some discussion on this would be helpful.

We agree that rGTP presence alone exhibited the greatest inhibition out of any of the single ribonucleotides tested. We hypothesize that the inhibition by rGTP is caused by factors in the telomeric sequence. Because the first templating base is an rC in our experimental setup, the first insertion event will be rGTP. In cases where that is successful, the next base in the sequence is also an rC, requiring the extension from a potentially unstable primer terminus, followed by yet another rGTP insertion. Therefore, telomerase cannot increase telomere length much past the initial primer terminus, potentially limiting the binding and keeping it engaged to the telomere end (with only three nucleotides base pairing). With all this in mind, we do concede that unknown effects specific to guanine could also be occurring, but we cannot test these effects without altering the telomere and TR sequences, which would alter insertion efficiencies of telomerase. We do think this adds to the Discussion, and have expanded on this in the manuscript:

"In the most extreme case of three rNTPs present per repeat, extension products are evident well into the second repeat, in contrast to the WT telomerase which had almost no insertion events (Figure 5E). We hypothesize that the rGTP insertion drastically inhibits WT telomerase because the first two insertions in the repeat are templated by rC. Therefore, the first event would need to be a rNTP insertion, followed by another rNTP insertion from a potentially unstable primer terminus. We are unable to decipher if inhibitory effects are due to the number of ribonucleotides per repeat, sequence-dependent inhibition, or a combination of both. In contrast to rGTP, telomerase is able to incorporate multiple repeats when rATP is present, albeit at a reduced efficiency compared to dNTPs (Figure 5E)."

> 12\) While all alterations resulted in reduction of telomere extension by telomerase, did any alterations tested enhance telomere extension (e.g. decreased pausing, improved processivity etc). This should be mentioned in the Discussion.

None of the alterations in this study enhanced telomerase extension and this is a mutation we are very interested in identifying in future studies. We have made a note emphasizing these results in the manuscript:

"Therefore, in order to prevent this telomeric disruption, the telomerase active site appears to have evolved a high degree of stringency towards noncanonical nucleotides, including both rNTPs and mismatched dNTPs. This stringency was evident by the reduced telomere elongation efficiency with every variant tested; other mutations could also be identified with this system that show increases in telomere elongation efficiency."

> 13\) Any evidence in the current series of experiment that the alterations of inserted ribonucleotides causes DNA damage or lack of shelterin protection. While this has been shown by others in cells using altered nucleotide insertion into telomeres, there are no cell-based studies in the present studies to confirm or progress much of the speculation in the Discussion since all experiments in the present studies use a somewhat artificial in vitro (test tube) approach. For example, do altered ribonucleotides persist in telomeres and is there any evidence that RER removes them? Also, what is the evidence that a single misinsertion every 10kb would prevent shelterin binding or disrupt G-quadruplex stability? Even with these concerns, the studies are important to help future studies confirm and extend these finding.

We would like to thank the reviewer for bringing up these points, and we agree that both the steady-state levels and the biological impacts of ribonucleotides and mismatches in telomere strands are pressing questions brought up by the current study. As such, we have more explicitly outlined the biological question that the present study brings to light. We are already establishing new techniques in our laboratory, including cell culture and modified telomere restriction fragment analysis to answer some of these questions, but they are as of yet unknown, and we believe outside of the scope of the current manuscript.

"While the downstream consequences of telomeric mismatches have not been studied in a biological context to our knowledge, they likely would disrupt G-quadruplex stability and inhibit shelterin protein binding, as both of these phenomena are dependent on DNA sequence (Figure 6B) (Burge, et al., 2006; de Lange, 2005)."

"...\[T\]elomerase inserts \~40 rNTPs, which represents selectivity comparable to DNA polymerase β and DNA polymerase δ (Brown and Suo, 2011; Cavanaugh, Beard and Wilson, 2010; McElhinny et al., 2010). However, it is unknown whether ribonucleotides persist in telomeres, their biological consequences, and if they are addressed with ribonucleotide excision repair (RER), similar to other genomic ribonucleotides (Sparks et al., 2012)."
